ClinicalTrials.gg
CompletedNCT07595263Updated Nov 10, 2026

A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019)

A Phase 1 interventional study of Ulonivirine and Methadone in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

Updated Nov 10, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is designed to determine the effect of ulonivirine (MK-8507) on methadone in the body. Participants will take methadone alone and then methadone with ulonivirine to see if ulonivirine changes how the body processes methadone.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main Inclusion Criteria include but are not limited to:

  • Is in good health
  • Has a (BMI) between >18 and ≤40 kg/m\^2
  • Is reliably participating in a methadone maintenance program for at least 2 months prior to Day 1 and is on a documented stable dose of methadone for at least 14 days prior to Day 1

Exclusion criteria

Exclusion Criteria

The main Exclusion Criteria include but are not limited to:

  • Has a history of cancer ()
  • Has a history of significant multiple and/or severe allergies, or has had an anaphylactic reaction or significant intolerability to prescription or nonprescription drugs or food
  • Has tested positive (HIV) or for a sexually transmitted infection at screening
  • Is under the age of legal consent
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Methadone + Ulonivirine

    Participants receive a stable dose of methadone orally from Day -14 through Day 16. Methadone is co-administered with one dose of oral ulonivirine on Day 2.

    Drug: Ulonivirine · Drug: Methadone

Interventions

06

What researchers measure

Primary outcomes

  1. Dose-Normalized Area Under the Plasma Concentration Time Curve From 0-24 Hours Postdose (AUC0-24) of R-Methadone

    The AUC0-24 of R-methadone will be determined on Day 1 (methadone) and Day 2 (methadone + ulonivirine).

    Time frame: Up to 24 hours post-dose

  2. Dose-Normalized AUC0-24 of S-Methadone

    The AUC0-24 of S-methadone will be determined on Day 1 (methadone) and Day 2 (methadone + ulonivirine).

    Time frame: Up to 24 hours post-dose

Secondary outcomes

  1. Dose-Normalized Maximum Plasma Concentration (Cmax) of R-Methadone

    The Cmax of R-methadone will be determined on Day 1 (methadone) and Day 2 (methadone + ulonivirine).

    Time frame: Up to 24 hours post-dose

  2. Dose-Normalized Plasma Concentration 24 Hours Postdose (C24) of R-Methadone

    The C24 of R-methadone will be determined on Day 1 (methadone) and Day 2 (methadone + ulonivirine).

    Time frame: 24 hours post-dose

  3. Time to Maximum Plasma Concentration (Tmax) of R-Methadone

    The Tmax of R-methadone will be determined on Day 1 (methadone) and Day 2 (methadone + ulonivirine).

    Time frame: Up to 24 hours post-dose

  4. Dose-Normalized Cmax of S-Methadone

    The Cmax of S-methadone will be determined on Day 1 (methadone) and Day 2 (methadone + ulonivirine).

    Time frame: Up to 24 hours post-dose

  5. Dose-Normalized C24 of S-Methadone

    The C24 of S-methadone will be determined on Day 1 (methadone) and Day 2 (methadone + ulonivirine).

    Time frame: 24 hours post-dose

  6. Tmax of S-Methadone

    The Tmax of S-methadone will be determined on Day 1 (methadone) and Day 2 (methadone + ulonivirine).

    Time frame: Up to 24 hours post-dose

  7. Dose-Normalized AUC0-24 of Total Methadone

    The AUC0-24 of total methadone will be determined on Day 1 (methadone) and Day 2 (methadone + ulonivirine).

    Time frame: Up to 24 hours post-dose

  8. Dose-Normalized Cmax of Total Methadone

    The Cmax of total methadone will be determined on Day 1 (methadone) and Day 2 (methadone + ulonivirine).

    Time frame: Up to 24 hours post-dose

  9. Dose-Normalized C24 of Total Methadone

    The C24 of total methadone will be determined on Day 1 (methadone) and Day 2 (methadone + ulonivirine).

    Time frame: 24 hours post-dose

  10. Tmax of Total Methadone

    The Tmax of total methadone will be determined on Day 1 (methadone) and Day 2 (methadone + ulonivirine).

    Time frame: Up to 24 hours post-dose

  11. Number of Participants With Adverse Events (AEs) Following Methadone + Ulonivirine Coadministration

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants experiencing an AE following coadministration of methadone and ulonivirine will be presented.

    Time frame: Up to 16 Days

  12. Number of Participants Discontinuing Study Therapy Due to AEs Following Coadministration of Methadone and Ulonivirine

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants discontinuing study therapy due to an AE following coadministration of methadone and ulonivirine will be presented.

    Time frame: Up to 16 Days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Aug 2026 to primary completion in Sep 2026, 1 month.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Jan 2027 → Sep 2026 and completion Jan 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
May 19, 2026
StartActual
Aug 17, 2026
Primary completionActual
Sep 29, 2026was Jan 2027
CompletionActual
Sep 29, 2026was Jan 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 10, 2026
Primary completion
Jan 15, 2027→Sep 29, 2026 (actual)
Nov 10, 2026
Study completion
Jan 15, 2027→Sep 29, 2026 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Recruiting→Completed
    Primary completion Jan 15, 2027→Sep 29, 2026 (now actual)
    Study completion Jan 15, 2027→Sep 29, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07595263
Responsible party
Sponsor
First posted
May 19, 2026
Start date
Aug 17, 2026
Primary completion
Sep 29, 2026
Completion
Sep 29, 2026
Last update
Nov 10, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ulonivirine · Methadone

Start the discussion